Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03614117
Other study ID # OTR/17.01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2, 2018
Est. completion date July 6, 2020

Study information

Verified date October 2020
Source ProbiSearch SL
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a new probiotic strain Lactobacillus salivarius PS7 on Acute Otitis Media (AOM) in children with recurrent AOM history. The study duration will be 7 months, which includes a 6-month product administration and a 1-month follow-up period. Participants will be randomized assigned to one of the three study groups: the control group; a 3 months probiotic +3 months placebo consumption group and a 6 months probiotic consumption group. The efficacy of the probiotic strain to reduce the incidence of AOM episodes will be assessed by counting AOM episodes occurring in study participants, during the entire intervention and follow-up periods, by bilateral comparison of each of the treatment groups with the control group according to the following hypothesis: "The number of AOM episodes occurring in participants who take the probiotic is the same as that for the participants in the control group. λc = λe". Where λc is the mean incidence of AOM in the control group and λe is the mean incidence of AOM in the groups taking the probiotic strain Lactobacillus salivarius PS7 obtained with 95% confidence interval.


Description:

The parent or legal guardian of the minors will be contacted during a visit to the pediatrician for suspected AOM to request their participation in the study, which will be voluntary. The study visits will take place at the primary care center or hospital. During Visit 1, the inclusion and exclusion criteria will be verified, and the informed consent will be signed. Information will be collected on the demographic profile, characteristics of the AOM episode and the prescribed treatment; and the participants will be randomized. The investigator will give the parent or guardian the product corresponding to the first treatment period (3 months) and will explain how to administer it to the child, as well as when the next visits will take place and what they will entail. Instructions will be given to start the administration of the product as soon as possible after the collection of the first stool sample. A sample will be collected from the outer ear most affected by the AOM using a sterile swab (Day 0). The investigator will go over, with the parent or legal guardian, the details of the diary to be completed (Annex II), how to record the data on product administration, fever episodes, days of school or daycare missed, unscheduled visits to the pediatrician, as well as data related to the frequency and characteristics of the stools in the event of AOM episodes and/or antibiotic treatment. The investigator will inform the parent or legal guardian that, during the child's participation in the study, the child cannot take any probiotic supplement. During Visit 2, a sample will be taken from the same ear as in the previous visit using a sterile swab. Any questions regarding completing the diary will be discussed. The leftover product from the first treatment period will be collected and the study product corresponding to the second supplement administration period will be dispensed. At the third visit (Visit 3, after 6 months of product administration), a sample will be collected from the same ear as in previous visits using a sterile swab. Any leftover product from the second treatment period will be collected. During the fourth visit (Visit 4, after 1 month of observation), a sample will be collected from the same ear as in previous visits using a sterile swab. The completed diary will be collected. Throughout the duration of the child's participation in the study (7 months), additional visits to the pediatrician (study investigator) may take place. If an episode of AOM, otitis externa or respiratory tract infection occurs during the intervention period, the investigator will make a diagnosis and will start the necessary treatment. In the course of new AOM episodes, during the intervention period, the administration of the product will not be interrupted. If the AOM episode occurs during the observation period, the investigator will proceed according to his/her routine practice. At the additional visits taking place, relevant data will be collected on the possible Adverse Events (AEs) or Serious Adverse Events (SAEs), as well as on the concomitant medication.


Recruitment information / eligibility

Status Completed
Enrollment 222
Est. completion date July 6, 2020
Est. primary completion date July 6, 2020
Accepts healthy volunteers No
Gender All
Age group 1 Year to 4 Years
Eligibility Inclusion Criteria: - Children 1 to 4 years of age with rAOM (3 episodes of AOM in the last 6 months, or 4 in the last 12 months). - Written informed consent signed by one of parents or legal guardian with the express or tacit consent of the other. - Presence of an AOM episode at the time of inclusion in the study. Exclusion Criteria: - chronic conditions under regular medication, such as asthma, allergic rhinitis… - congenital or acquired immunodeficiency, - taking systemic corticoid in the last 3 months for longer than 1 month - under present prophylactic antibiotic treatment - Down syndrome, - cleft lip or palate, - chronic tympanic perforation, - craniofacial abnormalities, - sleep apnea syndrome, - planned tympanostomy or tonsillectomy during the months of the study, - short bowel syndrome or any surgery in the gastrointestinal tract, - intestinal epithelial barrier defect (e.g., chronic diarrhea, intestinal inflammation), - metabolic disorders (diabetes, etc.), - heart failure and cardiac medical history (e.g. artificial heart valve, medical history of infective endocarditis, rheumatic fever or cardiac malformation), - uncertainty of the investigator regarding the willingness or capacity of the parents or legal guardian of the child to comply with the requirements of the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Lactobacillus salivarius PS7 during 6 months
7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
Lactobacillus salivarius PS7 during 3 months
7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
placebo
7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.

Locations

Country Name City State
Spain Hospital Universitario QuirónSalud Pozuelo Pozuelo De Alarcón Madrid

Sponsors (2)

Lead Sponsor Collaborator
ProbiSearch SL Casen Recordati S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Variables assessing compliance with the protocol The variables assessing compliance with the protocol
Study product administration.
Probiotic supplement administration
Compliance with the visit/assessment intervals.
7 months
Primary Number of AOM episodes Number of AOM episodes suffered by participants 7 months
Secondary Patients (%) with at least one AOM episode during the intervention and follow-up periods. % of patients with at least one AOM episode 7 months
Secondary Number of AOM episodes after 3 months of product intake. Number of AOM episodes suffered by participants after 3 months of product intake 3 months
Secondary Time from onset of first AOM episode to the onset of the next episode. Number of days from onset of first AOM episode to the onset of the next episode. 7 months
Secondary Adverse events and/or serious adverse events The number, duration and possible relationship of (serious) adverse events to the study product. 7 months
See also
  Status Clinical Trial Phase
Completed NCT02092454 - Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media Phase 2
Completed NCT01202578 - Evaluation of the Tympanostomy Tube Delivery System Phase 2/Phase 3
Withdrawn NCT00502450 - Is There Hearing Loss After Acute Mastoiditis N/A
Completed NCT04296448 - Evaluation of Cellphone Based Otoscopy in Pediatric Patients N/A
Terminated NCT05651633 - Analgesic Ear Drops for Children With Acute Otitis Media Phase 3
Completed NCT01941381 - Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media?
Completed NCT02345447 - Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence Phase 3
Recruiting NCT01214538 - Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children N/A
Recruiting NCT06027593 - Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions N/A
Completed NCT02918773 - Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto) N/A
Completed NCT02567747 - Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age
Completed NCT02935374 - Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children Phase 4
Completed NCT02567825 - Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media N/A
Completed NCT02037893 - Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media Phase 2
Completed NCT00578773 - A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea Phase 2
Completed NCT00377260 - Acute Otitis Media (AOM) Therapy Trial in Young Children Phase 4
Completed NCT00645112 - A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media Phase 4
Completed NCT00368823 - A Trial of Point of Care Information in Ambulatory Pediatrics Phase 3
Completed NCT01272999 - Impact of Prevnar 13 on Ear Infections in Children
Completed NCT01031082 - Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South African Children N/A